文献速递湿疹皮炎与荨麻疹

曲罗芦单抗治疗通过增加微生物多样性改善中重度特应性皮炎成人患者的皮肤微生物群:ECZTRA 1随机对照试验的微生物多样性分析

Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2022-12-05

基于3期ECZTRA 1试验(NCT03131648)中重度特应性皮炎成人患者子集,评估曲罗芦单抗对皮损皮肤微生物组的影响;结果显示治疗增加微生物多样性、降低金黄色葡萄球菌丰度并增加凝固酶阴性葡萄球菌丰度,作者认为靶向白介素13可直接和/或间接改善皮肤微生物失调。

要点

  • 曲罗芦单抗治疗增加中重度特应性皮炎患者皮损皮肤微生物多样性。
  • 治疗降低皮损皮肤金黄色葡萄球菌丰度。
  • 治疗增加共生凝固酶阴性葡萄球菌丰度。

核心结论

  • 作者认为,使用曲罗芦单抗特异性靶向白介素13细胞因子可直接和/或间接改善特应性皮炎皮肤中所见的微生物失调。

研究设计与样本

  • 3期ECZTRA 1试验(NCT03131648)的子集分析,评估中重度特应性皮炎成人患者皮损皮肤的微生物组。

主要发现

  • 曲罗芦单抗治疗导致微生物多样性增加。
  • 曲罗芦单抗治疗降低金黄色葡萄球菌丰度。
  • 曲罗芦单抗治疗增加共生凝固酶阴性葡萄球菌丰度。

局限性

  • 缺乏第8周的金黄色葡萄球菌丰度数据。
  • 参与者之间采样部位存在差异。
  • 可能受到合并使用全身抗感染药物的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is characterized by microbial dysbiosis, immune dysregulation, and an impaired skin barrier. Microbial dysbiosis in AD involves a reduction in diversity primarily driven by an increased abundance of Staphylococcus aureus. Tralokinumab, an approved treatment for adults with moderate-to-severe AD, improves the skin barrier and immune abnormalities by specifically targeting the interleukin 13 cytokine, but its impact on the skin microbiome is unknown. OBJECTIVE: To investigate how tralokinumab affects the skin microbiome by examining the lesional skin of adults with moderate-to-severe AD from the phase 3 ECZTRA 1 trial (NCT03131648). METHODS: Microbiome profiling, S aureus abundance, and biomarker data were assessed in a subset of ECZTRA 1 participants (S aureus abundance at baseline and week 16; microbiome profiling at baseline, and week 8/16; and serum sampling before dose and week 4/8/16/28/52). RESULTS: Tralokinumab treatment led to increased microbial diversity, reduced S aureus abundance, and increased abundance of the commensal coagulase-negative Staphylococci. LIMITATIONS: Limitations include a lack of S aureus abundance data at week 8, sampling site variation between participants, and possible influence from concomitant systemic antiinfectives. CONCLUSION: Our findings indicate specific targeting of the interleukin 13 cytokine with tralokinumab can directly and/or indirectly improve microbial dysbiosis seen in AD skin.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. 2022. PMID: 36473633. doi:10.1016/j.jaad.2022.11.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。